CN103705452A - Antibacterial drug injection containing poloxamer 407 and oily medium - Google Patents
Antibacterial drug injection containing poloxamer 407 and oily medium Download PDFInfo
- Publication number
- CN103705452A CN103705452A CN201410005508.0A CN201410005508A CN103705452A CN 103705452 A CN103705452 A CN 103705452A CN 201410005508 A CN201410005508 A CN 201410005508A CN 103705452 A CN103705452 A CN 103705452A
- Authority
- CN
- China
- Prior art keywords
- injection
- medicine carrying
- antibacterials
- preparation
- carrying microgranule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 69
- 239000007924 injection Substances 0.000 title claims abstract description 69
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 title abstract description 4
- 229940124350 antibacterial drug Drugs 0.000 title abstract 3
- 229920001992 poloxamer 407 Polymers 0.000 title abstract 3
- 229940044476 poloxamer 407 Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 95
- 239000003814 drug Substances 0.000 claims abstract description 79
- 238000000227 grinding Methods 0.000 claims abstract description 5
- 239000004531 microgranule Substances 0.000 claims description 46
- 230000000844 anti-bacterial effect Effects 0.000 claims description 33
- 229940088710 antibiotic agent Drugs 0.000 claims description 33
- 239000003921 oil Substances 0.000 claims description 29
- 235000019198 oils Nutrition 0.000 claims description 29
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 18
- KEQFDTJEEQKVLM-JUODUXDSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydron;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 KEQFDTJEEQKVLM-JUODUXDSSA-N 0.000 claims description 14
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 14
- 229960001356 ceftiofur hydrochloride Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims description 10
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 10
- 229960000740 enrofloxacin Drugs 0.000 claims description 10
- 229940044519 poloxamer 188 Drugs 0.000 claims description 10
- 229920001993 poloxamer 188 Polymers 0.000 claims description 10
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 229960003760 florfenicol Drugs 0.000 claims description 9
- 239000001530 fumaric acid Substances 0.000 claims description 9
- 229960004885 tiamulin Drugs 0.000 claims description 9
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- CUJMCPPBTUATEJ-UHFFFAOYSA-N 1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)ethanone Chemical compound C1=CC=C2[N+](=O)C(C(=O)C)=C(C)N([O-])C2=C1 CUJMCPPBTUATEJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003276 erythromycin Drugs 0.000 claims description 7
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims description 7
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims description 7
- MYDXUJMODAZBGN-UHFFFAOYSA-N 6-bromo-5-methyl-2-methylsulfanyl-1h-[1,2,4]triazolo[1,5-a]pyrimidin-7-one Chemical compound CC1=C(Br)C(=O)N2NC(SC)=NC2=N1 MYDXUJMODAZBGN-UHFFFAOYSA-N 0.000 claims description 6
- 241001619326 Cephalosporium Species 0.000 claims description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 229960004745 danofloxacin mesylate Drugs 0.000 claims description 6
- -1 for meter Ke Xing Chemical compound 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 239000001117 sulphuric acid Substances 0.000 claims description 6
- 235000011149 sulphuric acid Nutrition 0.000 claims description 6
- DVWJFTGEISXVSH-CWVFEVJCSA-N (1R,3S,5S,7Z,11R,12S,13Z,15Z,17Z,19Z,21R,23S,24R,25S)-21-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-12-ethyl-1,3,5,25-tetrahydroxy-11-methyl-9-oxo-10,27-dioxabicyclo[21.3.1]heptacosa-7,13,15,17,19-pentaene-24-carboxylic acid Chemical compound CC[C@H]1\C=C/C=C\C=C/C=C\[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@@H](O)C\C=C/C(=O)O[C@@H]1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O DVWJFTGEISXVSH-CWVFEVJCSA-N 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 229930183279 tetramycin Natural products 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004182 Tylosin Substances 0.000 claims description 3
- 229930194936 Tylosin Natural products 0.000 claims description 3
- 229960002531 marbofloxacin Drugs 0.000 claims description 3
- YKQOSKADJPQZHB-RGYSVOEGSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(6r,9s,12r,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydr Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-RGYSVOEGSA-N 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 229960004059 tylosin Drugs 0.000 claims description 3
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims description 3
- 235000019375 tylosin Nutrition 0.000 claims description 3
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 51
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000084 colloidal system Substances 0.000 description 18
- 239000004576 sand Substances 0.000 description 18
- 239000006104 solid solution Substances 0.000 description 14
- 238000010257 thawing Methods 0.000 description 11
- 238000001816 cooling Methods 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 230000006837 decompression Effects 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000009835 boiling Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960000223 tilmicosin Drugs 0.000 description 5
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 3
- 229960005229 ceftiofur Drugs 0.000 description 3
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940069952 erythromycin injection Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000012353 Contagious Pleuropneumonia Diseases 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229950009592 cefquinome Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000008977 mycoplasmal pneumonia of swine Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410005508.0A CN103705452B (en) | 2014-01-07 | 2014-01-07 | Containing the antibacterials injection of poloxamer188 and oil medium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410005508.0A CN103705452B (en) | 2014-01-07 | 2014-01-07 | Containing the antibacterials injection of poloxamer188 and oil medium |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103705452A true CN103705452A (en) | 2014-04-09 |
CN103705452B CN103705452B (en) | 2016-01-06 |
Family
ID=50399049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410005508.0A Active CN103705452B (en) | 2014-01-07 | 2014-01-07 | Containing the antibacterials injection of poloxamer188 and oil medium |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103705452B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095871A (en) * | 2014-07-10 | 2014-10-15 | 青岛蔚蓝生物股份有限公司 | Veterinary injection containing lincomycin hydrochloride and spectinomycin sulfate |
WO2016138339A1 (en) * | 2015-02-26 | 2016-09-01 | Merial, Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
CN113288867A (en) * | 2020-02-24 | 2021-08-24 | 东莞市东阳光动物保健药品有限公司 | Marbofloxacin composition and preparation method thereof |
CN117982413A (en) * | 2024-04-03 | 2024-05-07 | 山东恒邦中科生物工程有限公司 | Preparation method of cefquinome sulfate injection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101703776A (en) * | 2009-09-28 | 2010-05-12 | 洛阳惠中兽药有限公司 | Method for preparing anti-infective agent long-acting injection |
-
2014
- 2014-01-07 CN CN201410005508.0A patent/CN103705452B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101703776A (en) * | 2009-09-28 | 2010-05-12 | 洛阳惠中兽药有限公司 | Method for preparing anti-infective agent long-acting injection |
Non-Patent Citations (2)
Title |
---|
周巧云 等: "泊洛沙姆为载体的疏水性药物新剂型研究进展", 《中国现代应用药学》 * |
胡兴平: "固体分散技术的研究进展及应用", 《兽药研究与应用》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095871A (en) * | 2014-07-10 | 2014-10-15 | 青岛蔚蓝生物股份有限公司 | Veterinary injection containing lincomycin hydrochloride and spectinomycin sulfate |
WO2016138339A1 (en) * | 2015-02-26 | 2016-09-01 | Merial, Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
AU2016222532B2 (en) * | 2015-02-26 | 2018-07-12 | Boehringer Ingelheim Animal Health USA Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
AU2018205137B2 (en) * | 2015-02-26 | 2019-08-08 | Boehringer Ingelheim Animal Health USA Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
US10561641B2 (en) | 2015-02-26 | 2020-02-18 | Boehringer Ingelheim Animal Health USA Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
EA035993B1 (en) * | 2015-02-26 | 2020-09-10 | Мериал, Инк. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
US11484528B2 (en) | 2015-02-26 | 2022-11-01 | Boehringer Ingelheim Animal Health USA Inc. | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
CN113288867A (en) * | 2020-02-24 | 2021-08-24 | 东莞市东阳光动物保健药品有限公司 | Marbofloxacin composition and preparation method thereof |
CN113288867B (en) * | 2020-02-24 | 2024-04-26 | 东莞市东阳光动物保健药品有限公司 | Marbofloxacin composition and preparation method thereof |
CN117982413A (en) * | 2024-04-03 | 2024-05-07 | 山东恒邦中科生物工程有限公司 | Preparation method of cefquinome sulfate injection |
Also Published As
Publication number | Publication date |
---|---|
CN103705452B (en) | 2016-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103705452B (en) | Containing the antibacterials injection of poloxamer188 and oil medium | |
CN101396334B (en) | Curcumin lipid carrier and preparation method thereof | |
CN102631347A (en) | Gefinitib medicinal composite and method for preparing same | |
CN101088524A (en) | Phosphatide composition of active skull cap components and its prepn process and prepn | |
CN103720652B (en) | Prepare containing Avermectins medicine injection with poloxamer and oil medium | |
CN102626384A (en) | Curcumin suspension and preparation method thereof | |
CN105287607B (en) | Animal compound Doxycycline Hyclate florfenicol slowly-releasing microballoon suspension injection | |
Bhowmik et al. | Solid dispersion-a approach to enhance the dissolution rate of poorly water soluble drugs | |
CN103211751A (en) | Medical composition containing vilazodone and preparation method thereof | |
CN103705454A (en) | Oily injection containing valnemulin hydrochloride/poloxamer 407 | |
CN103721263A (en) | Oil injection containing antibacterial agents/polyethylene glycol drug-loading particles | |
CN102961368A (en) | Curcumin nanosuspension and preparation method thereof | |
CN102429918A (en) | Medicinal composition containing florfenicol and tea saponin and preparation method thereof | |
CN104415340A (en) | Solid drug preparation and preparing method thereof | |
CN103550149A (en) | Technology for preparing long-acting injection containing antiparasitic drugs | |
CN108619142B (en) | A kind of long-acting composite florfenicol injection and preparation method thereof | |
CN103463088B (en) | A kind of compositions of daily treatment flu and soft capsule | |
CN103705455A (en) | Injection containing non-steroidal anti-inflammatory drug and prepared by use of poloxamer and oily medium | |
CN103932974B (en) | Ciclopirox olamine vaginal suppository composition and preparation method thereof | |
JP5753089B2 (en) | Method for obtaining a stable dispersion of benzoyl peroxide | |
CN103705453B (en) | Oily injection containing doxycycline hydrochloride/poloxamer drug-loading particles | |
CN101401788B (en) | Self-emulsifying formulation of biphenyldicarboxylate and preparation method thereof | |
CN103705456A (en) | Oily injection containing tiamulin hydrogen famarate/polyethylene glycol medicine carrying particles | |
CN102908377B (en) | Legalon dispersing tablet and preparation method thereof | |
CN103432074B (en) | Praziquantel emulsion injection and preparation technology thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Patent contact of Hepburn (Beijing) Pharmaceutical Co.,Ltd. Document name: Notification that Application Deemed not to be Proposed |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170110 Address after: 102206 Beijing City, Changping District Shahe Airport Industrial Park No. 535 road Wang Lin Patentee after: Hogben (Beijing) Pharmaceutical Co.,Ltd. Address before: 100083 Beijing Qinghua East Road, No. 17,, 41-5-102 Patentee before: Wang Yuwan |
|
DD01 | Delivery of document by public notice |
Addressee: Hogben (Beijing) Pharmaceutical Co.,Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
CP03 | Change of name, title or address |
Address after: 102299 Room 2171, Block 9 B, Qianqian Road, Changping District Science and Technology Park, Beijing Patentee after: Hogben (Beijing) Pharmaceutical Co.,Ltd. Country or region after: Zhong Guo Address before: 102206 Lin535, Wangzhuang Industrial Park, Shahe Airport Road, Changping District, Beijing Patentee before: Hogben (Beijing) Pharmaceutical Co.,Ltd. Country or region before: Zhong Guo |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240321 Address after: 435300 Jinshan Road, Hexi Lishizhen Pharmaceutical Industrial Park, Qichun County, Huanggang City, Hubei Province, No. 008-8 Patentee after: Hubei Shizhen Health Research Co.,Ltd. Country or region after: Zhong Guo Address before: 102299 Room 2171, Block 9 B, Qianqian Road, Changping District Science and Technology Park, Beijing Patentee before: Hogben (Beijing) Pharmaceutical Co.,Ltd. Country or region before: Zhong Guo |
|
TR01 | Transfer of patent right |